Taiwan News20 小时
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at ...
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in ...